Medtech group Tissue Regenix (LON:TRX) has put the framework of a US sales force in place ahead of the launch of its first product.
The regenerative tissue specialist has signed seven regional sales distribution agreements to cover 25 US states.
The seven distributors signed up so far represent over 40 sales people who will promote DermaPure in US acute care hospitals, Veteran Affairs (VA) Hospitals and institutions as well as Long Term Acute Care hospitals (LTACs).
Further distribution agreements are planned to fill in the gaps and ensure coverage of all major US cities by the end of 2014, Tissue Regenix said.
Dermapure, a skin replacement for chronic and acute wounds, is scheduled to launch early next year. Chromic wound care is US$1.5bn annual market in the US with 6.5mln patients affected each year.
DermaPure uses human donor skin, which is washed by Tissue’s dCELL process to remove the DNA and cells but leave a natural biological scaffold.
This is then placed in the wound to be repopulated by the patient's own cells, which promotes quicker more effective healing.
Tissue Regenix has partnered with Community Tissue Services (CTS), one of the largest tissue banks in North America, which will supply the human tissue.